NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
NITTO DENKO CORPORATION (Japan)
Inventor
Sato, Yusuke
Harashima, Hideyoshi
Hashiba, Kazuki
Taguchi, Masamitsu
Sakamoto, Sachiko
Shishido, Takuya
Otsu, Ayaka
Maeda, Yoshiki
Abstract
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a straight-chain or branched-chain C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B) (d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I): (R1)(R2)C(OH)-(CH2)a-(O-CO)b-X. (A): (R11)(R12)-CH-(CO-O)c-(CH2)v-. (B): -(CH2)d-N(R3)(R4).
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
2.
METHOD OF TREATING OIL-CONTAINING DISCHARGED WATER
The present invention involves processing, by using an oil resistance separation membrane, a to-be-processed liquid that is obtained from an oil-containing wastewater and that contains oil, to remove said oil therefrom.
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
The present invention pertains to a coating material containing a resin component and at least one oil component P, wherein below a predetermined temperature, the oil component P can be exuded from a coating layer cured and dried after the application of the coating material, the wetting parameter is 0.5 (J/cm3)1/2 or less, and the gel percentage in the coating layer is 30% or more.
C09D 201/00 - Coating compositions based on unspecified macromolecular compounds
C09K 3/18 - Materials not provided for elsewhere for application to surface to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
This biosensor is attached to a living body to obtain signals from the living body, the biosensor comprising: a cover member; and a porous substrate having a porous structure and provided to the cover member on the living body side thereof. An attachment layer has the porous substrate and a first adhesive layer provided to the porous substrate on the living body side thereof, and the attachment layer: demonstrates a shear stress of 5×104 N/m2 to 65×104 N/m2 when deformed by 5% to 15% of the length of the attachment layer in a direction perpendicular to the thickness direction of the attachment layer; and has a moisture permeability of 65 (g/m2·day) to 4000 (g/m2·day).
The present invention addresses the problem of providing a patch preparation having excellent drug skin permeability and excellent adhesive properties. The present invention relates to a patch preparation characterized by containing, in an adhesive layer, a drug (other than tandospirone and pharmaceutically acceptable salts thereof), levulinic acid, and a propylene glycol fatty acid ester. The patch preparation has practical adhesive properties and is excellent in the skin permeability of the drug.
A ventilation component 1a is provided with an inner member 10, a ventilation film 20, and an outer member 30. The inner member 10 has an open tube structure and has a protruding portion 11 on the outer circumferential surface of the open tube structure. The ventilation film 20 covers one opening of the inner member. The outer member 10 is formed as a closed tube structure and has a locking portion for locking the protruding portion 11 at the inner circumferential surface of the closed tube structure. The inner member 10 is secured to the outer member 30 in a state in which the inner member 10 is inserted into the interior of the outer member 30 and the outer member 30 locks the protruding portion 11 by means of a locking portion 33. The ventilation component 1a can be secured to a protrusion 2p protruding in a tubular shape on the outer surface of a housing 2. When viewed in a planar view along an axial line A of the inner member 10 and the outer member 30, the ventilation component 1a satisfies the condition IH
Provided is a stick-on biosensor which is capable of obtaining good biological information. The stick-on biosensor includes: a pressure sensitive adhesive layer and an electrode part, said pressure sensitive adhesive layer having a stick-on surface that is attached to a subject; a base material layer that is provided on top of the opposite side of the pressure sensitive adhesive layer from the stick-on surface; and an electronic device that is provided on the base material layer and processes a biosignal obtained through the electrode part. The structure including the pressure sensitive adhesive layer, the electrode part, and the base material layer has a flexural rigidity of 0.010 [MPa·mm3/mm] or more, and the adhesive force with which the electrode part adheres to the subject is greater than 0.6 [N/cm2] and less than or equal to 5.0 [N/cm2].
The purpose of the present invention is to enable acquisition of data using less power. This data acquisition apparatus has an integrated circuit and an information processing device. The integrated circuit has: a first terminal to which a switch signal for master/slave switching is input at the start of acquisition of data; an A/D inverter for converting input analogue data to digital data; and an output terminal for outputting the digital data. In response to the switch signal, the integrated circuit is set as a master or slave. The information processing device has: a switching setting unit which, when the integrated circuit is a slave, sets the information processing device as a master, when the integrated circuit is a master, sets the information processing device as a slave, and generates the switch signal; a second terminal which is connected to the first terminal and outputs the switch signal; and an input terminal which is connected to the output terminal and to which the digital data is input. When the integrated circuit is set as a master on the basis of the switch signal input from the information processing device, the integrated circuit outputs the digital data from the output terminal.
The objective of the present invention is to provide a film for increasing snow slippage and with which excellent prevention of snow adhesion and/or ice adhesion onto a structure can be achieved. This film includes as the outermost layer an oil-containing layer that contains an oil component within a resin. The oil component bleeds from the surface of the oil-containing layer at a predetermined temperature or lower. The surface of the oil-containing layer has a textured shape. In a 3.2 cm × 3.2 cm region on the surface of the oil-containing layer, the calculated mean height (Sa) is 4 µm or more.
B29C 59/04 - Surface shaping, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing using rollers or endless belts
B32B 3/30 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a layer with cavities or internal voids characterised by a layer formed with recesses or projections, e.g. grooved, ribbed
C08J 5/16 - Manufacture of articles or materials having reduced friction
C09K 3/18 - Materials not provided for elsewhere for application to surface to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
E04H 9/16 - Buildings, groups of buildings or shelters adapted to withstand or provide protection against abnormal external influences, e.g. war-like action, earthquake or extreme climate against adverse conditions, e.g. extreme climate, pests
10.
SOLAR CELL STRUCTURE AND METHOD FOR PREVENTING SNOW PILING ONTO SOLAR CELL STRUCTURE
This solar cell structure comprises: a panel structure having a solar cell panel; and a stand that supports the panel structure in an inclined state. The stand includes a support surface that supports the panel structure. The solar cell structure further comprises a cover that covers at least a region from the lower edge of the support surface in the direction of inclination to a prescribed area above the solar cell panel.
Described herein is an ammonia compound indicator comprising an adhesive and a chemochromic compound disposed therein. Also described are methods of making the aforedescribed elements and methods for indicating the presence of ammonia.
G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
G01M 3/04 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point
G01M 3/20 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroups; Apparatus specially adapted for such methods using chemical indicators
The purpose of the present invention is to provide products, in particular, a coating material, capable of preventing icing and/or snow accretion. The coating material comprises a first oil ingredient, a second oil ingredient, and a first resin precursor, which is a precursor of a resin ingredient. Curing the first resin precursor which contains the first and second oil ingredients gives an oil-containing resin layer comprising the first and second oil ingredients and the resin ingredient. The second oil ingredient constitutes a low-temperature separable oil ingredient which, when the temperature declines to or below a given value, can separate from the first-oil-ingredient phase to ooze out of the oil-containing resin layer.
The purpose of the present invention is to provide a sheet body that has an improved ice-accretion and/or snow-accretion inhibitory function. This sheet body comprises at least: an oil-containing resin layer that is in the form of a solid and that contains an oil; and an oil-permeable superficial resin layer which has a higher abrasion resistance than the oil-containing resin layer and which is laminated on one surface of the oil-containing resin layer. The oil contained in the oil-containing resin layer comprises a low-temperature exudative oil component that is capable of exuding from the oil-containing resin layer when the temperature drops to a level equal to or lower than a prescribed value, while the superficial resin layer exhibits oil permeability that allows the low-temperature exudative oil component exuding from the oil-containing resin layer to permeate the superficial resin layer up to a surface that is situated on the side opposite to the oil-containing resin layer.
E04H 9/16 - Buildings, groups of buildings or shelters adapted to withstand or provide protection against abnormal external influences, e.g. war-like action, earthquake or extreme climate against adverse conditions, e.g. extreme climate, pests
A biosensor sheet includes a pressure-sensitive adhesive layer for attaching to a surface of a living body, and a probe disposed on the pressure-sensitive adhesive layer, wherein the probe has an exposure region in which the pressure-sensitive adhesive layer is exposed.
Provided is an internal pressure adjustment member for attaching to the outer surface of a case, that: has high air permeability even when the pressure difference that may occur between inside and outside of the attachment case is small; and reduces damage and air permeability deterioration caused by flying dirt and mud. This internal pressure adjustment member comprises: a filter including a net- or mesh-shaped support layer and first and second polytetrafluorethylene (PTFE) porous membranes laminated on the support layer so as to sandwich the support layer, said filter having the first PTFE porous membrane exposed on one surface and the second PTFE porous membrane exposed on the other surface; and an adhesive section formed on said one surface of the filter and being for attaching the filter to the outer surface of the case. The average pore diameter of the first and second PTFE porous membranes is at least 2.0 µm, respectively, the thickness of the filter is no more than 140 µm, and the density of the filter is no more than 0.60 g/cm3.
This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Described herein is a graphene and polyvinyl alcohol based multilayer composite membrane that provides selective resistance for solutes to pass the membrane while providing water permeability. A selectively permeable membrane comprising a crossiinked graphene with a polyvinyl alcohol and silica-nanoparticle layer that can provide enhanced salt separation from water, methods for making such membranes, and methods of using the membranes for dehydrating or removing solutes from water are also described.
The present invention relates to: a carrier for delivering a retinoid-containing substance used by extracellular-matrix-producing cells in the skin; a skin fibrosis treatment agent using said carrier; a preparation kit for said treatment agent; a production method for said carrier; and a production method for said treatment agent.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
AGENT FOR INDUCING CELL DEATH, AGENT FOR SUPPRESSING CELL PROLIFERATION, AND PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF DISEASE RESULTING FROM ABNORMAL CELL PROLIFERATION
It becomes possible to induce cell death of cancer cells and inhibit cell proliferation of cancer cells. A medicinal agent capable of inhibiting both of GST-p and MRPL17 is contained as an active ingredient, or a medicinal agent capable of inhibiting GST-p and a medicinal agent capable of inhibiting MRPL17 are contained as active ingredients.
Described herein is a crosslinked graphene based composite membrane that provides selective resistance to fluids solutes while providing water permeability, such as a selectively permeable membrane comprising a crosslinked graphene with a polyvinyl alcohol and silica-nanoparticle layer that can provide enhanced water separation. Also described herein are methods for making such membranes and methods of using the membranes for dehydrating or removing solutes from water.
The invention relates to a functionalized laminated optical element comprising: - An optical base element; - A functional film structure consisting of a single layer or a multilayer structure; - A layer of a pressure-sensitive adhesive of optical quality, placed between one surface of the optical base element and the functional film structure so as to permanently retain said functional film structure on the surface of the optical base element. Said functionalized laminated optical element maintains its integrity after typical processing of an optical article which includes wheel edging. More particularly the invention relates to the use of a specific adhesive system for improving the wheel edging resistance of functionalized laminated optical element. The functional laminated optical may be an ophthalmic lens.
This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2'-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
Described herein is a graphene material based membrane that provides selective resistance for solutes or gas while providing water permeability. A selectively permeable membrane comprising graphene oxide, reduced graphene oxide, and also functionalized or crosslinked between the graphene, that provides enhanced salt separation from water or gas permeability resistance, methods for making such membranes, and methods of using the membranes for dehydrating or removing solutes from water are also described.
This air filter material (10) comprises a first polytetrafluoroethylene (PTFE) porous membrane (1) and a second PTFE porous membrane (2). Fibers included in the first PTFE porous membrane (1) have an average fiber diameter of 0.24-0.45 µm, whereas fibers included in the second PTFE porous membrane (2) have an average fiber diameter of 0.04-0.23 µm. The air filter material (10) has a first main surface (11) and a second main surface (12), and the first PTFE porous membrane (1) and the second PTFE porous membrane (2) are disposed such that an airstream flowing from the first main surface (11) to the second main surface (12) passes through the first PTFE porous membrane (1) and the second PTFE porous membrane (2) in this order.
Described herein is a selectively permeable membrane comprising a graphene oxide and a polyvinyl alcohol on a support that provides high moisture permeability and low gas permeability. The methods for making these selectively permeable membranes and related devices are also described.
This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.
This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 235/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 333/04 - Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 211/42 - Oxygen atoms attached in position 3 or 5
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A patch preparation capable of inhibiting a deviation in pressure-sensitive adhesive properties of a pressure-sensitive adhesive layer even elapsing a long period of time until it is used after production and capable of keeping favorable pressure-sensitive adhesive properties is provided. The patch preparation includes a support and a pressure-sensitive adhesive layer formed on one surface of the support, and the pressure-sensitive adhesive layer includes: (A) a polymer prepared by copolymerizing monomer components including a hydroxyl group-containing monomer and an alkyl (meth)acrylate monomer; (B) a polymer prepared by copolymerizing monomer components including a methyl methacrylate monomer and a butyl methacrylate monomer; and (C) a basic drug, provided that bisoprolol and a salt thereof are excluded.
Provided is a PSA composition for forming a PSA comprising a (meth)acrylic polymer, comprising, as monomeric components constituting the (meth)acrylic polymer: (A) a C2-18 alkyl (meth)acrylate, (B) an alicyclic monomer, and (C) a monomer having at least either a hydroxyl group or a carboxyl group. The average number of carbons of alkyl group in the (A) is 8 or less. The monomeric components comprise the (C) at 3 % by weight or greater while the weights Wb and Wc of the (B) and (C) satisfy a relationship 0.8 <= Wb/Wc.
C09J 133/08 - Homopolymers or copolymers of acrylic acid esters
30.
CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, GROWTH SUPPRESSING AGENT FOR SAME CELLS AND PHARMACEUTICAL COMPOSITION FOR THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SAME CELLS
The present invention induces cell death and/or inhibits cell proliferation for cells having a mutation in the BRAF gene. The present invention includes, as an active ingredient, a drug inhibiting GST-p.
The present invention induces cell death, and suppresses cell growth, in cancer cells. The invention includes as active ingredients a drug for suppressing GST-p and a drug for suppressing both GST-p and suppressing homeostasis- and maintenance-related proteins exhibiting synthetic lethality.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
This invention provides compounds, compositions and methods for modulating the expression of human GST-pi using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2'-deoxy nucleotides located in the seed region, as well as other nucleotide modifications
The invention disclosed herein relates to a polymer conjugate characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the backbone of the polymer, a polymer micelle derived from the polymer conjugate, a composition comprising the polymer micelle, and a method for treating a disease or condition using thereof.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targeting ability to peptide (1), and (3) a peptide mimetic having a comparable targeting ability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
An infrared-ray reflective film (100) of the present invention is configured by disposing an infrared reflective layer (20) and a transparent protective layer (30) on a transparent film backing (10) in this order. The infrared reflective layer (20) comprises: a first metal oxide layer (21); a metal layer (25) made of a silver alloy containing silver in an amount of 96 to 99.9 weight%; and a second metal oxide layer (22), which are arranged in this order from the side of the transparent film backing (10), wherein each of the first metal oxide layer (21) and the second metal oxide layer (22) is in direct contact with the metal layer (25). There is no metal layer between the transparent film backing (10) and the infrared reflective layer (20) and between the infrared reflective layer (20) and the transparent protective layer (30). Preferably, the infrared-ray reflective film of the present invention has a visible ray transmittance of 65% or more, a shading coefficient of less than 0.60, and a corrected emissivity as measured from the side of the transparent protective layer of 0.20 or less.
The present invention relates to a composition for enhancing transdermal absorption of a drug, containing a polyvalent alcohol having 3 to 8 carbon atoms, an organic acid having 2 to 20 carbon atoms, and a higher alcohol having 12 to 20 carbon atoms, and a patch preparation containing a support and a drug-containing adhesive layer containing the composition on one surface of the support.
Disclosed is an infrared reflective film (100) configured by disposing an infrared ray reflective layer (20) and a transparent protective layer (30) on a transparent film backing (10) in this order. The infrared ray reflective layer (20) comprises: a first metal oxide layer (21); a metal layer (25) comprising a primary component consisting of silver; and a second metal oxide layer (22) comprised of a composite metal oxide containing zinc oxide and tin oxide, which are arranged in this order from the side of the transparent film backing (10). The transparent protective layer (30) lies in direct contact with the second metal oxide layer (22). The transparent protective layer (30) has a thickness of 30 nm to 150 nm, and is preferably an organic layer having a cross-linked structure derived from an ester compound having an acidic group and a polymerizable functional group in the same molecule. Preferably, an amount of the ester compound-derived structure contained in the transparent protective layer (30) is 1 to 40 weight%.
E04B 1/76 - Heat, sound or noise insulation, absorption, or reflection; Other building methods affording favourable thermal or acoustical conditions, e.g. accumulating of heat within walls specifically with respect to heat only
38.
APOPTOSIS-INDUCING AGENT COMPRISING SUPPRESSORS OF GST-.PI. AND AKT
The purpose of the present invention is to provide a composition for effectively inducing apoptosis and/or proliferation inhibition in a cell, and a method using the same. An agent for inducing apoptosis that comprises as active ingredients a drug inhibiting GST-p and a drug inhibiting Akt; a medicinal composition comprising the same; a method for treating a disease caused by abnormality in apoptosis using the same, etc.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The purpose of the present invention is to provide a novel tissue regeneration accelerator and tissue regeneration method. The present invention relates to: a composition for accelerating tissue regeneration, accelerating cell differentiation and/or accelerating cell multiplication comprising a component selected from the group consisting of activated stellate cells, the decomposition product of activated stellate cells, MMP14, collagen that has been treated with MMP14, and the secretion product of activated stellate cells; a composition for suppressing cell multiplication comprising MMP14 suppressing material; and a cell cultivation substrate comprising collagen that has been treated with MMP14.
The present invention provides a patch preparation containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a drug, amine oxide, a low-polar liquid component based on an organic compound having an angle of 0 - 19° as calculated by the formula (I): angle (°)=arctan (inorganic value/organic value) × (180/.pi.) and using an inorganic value and an organic value on an organic conceptual diagram, and an adhesive base, and the adhesive layer has an amine oxide content of 0.1 - 5 wt% and a low-polar liquid component content of 30 - 50 wt%.
The present invention provides a transdermal patch or a transdermal preparation in which anchoring to a support body of an adhesive layer is improved without negatively affecting adhesive properties such as adherence, adhesiveness, and cohesiveness. The support body of the present invention is a support body for a transdermal patch or transdermal preparation provided with a plastic film-containing substrate, and an undercoat agent layer layered on the substrate, wherein the undercoat agent layer contains porous inorganic particles having a mean particle size of 1 µm to 15 µm. This transdermal patch or transdermal preparation is provided with the support body and an adhesive layer arranged so as to be adjacent to the undercoat agent layer on one surface of the support body.
An object of the present invention is to provide a packaging material that is capable of long term storage by preventing adsorption or transfer of an easily oxidizable component and an oily component in an adhesive of a patch to the packaging material, and also preventing discoloration and decrease in drug effect due to oxidization. The present invention provides the packaging material for a patch including: an inner layer made of polyethylene terephthalate having heat sealing properties; an oxygen-absorbing layer that includes an oxygen-absorbing resin having an unsaturated alicyclic structure as an oxygen-absorbing part; and an oxygen barrier layer made of aluminum foil as an outer layer.
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
B32B 15/09 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising polyesters
B32B 33/00 - Layered products characterised by particular properties or particular surface features, e.g. particular surface coatings; Layered products designed for particular purposes not covered by another single class
43.
LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
The description is directed to ionizable lipid compounds of formula I or pharmaceutically acceptable salts thereof, which are useful for enhancing the delivery of therapeutic agents in liposomes to cells, tissues, and organisms. Compositions, pharmaceutical formulations, drug carriers and methods of using the compounds of formula I are also provided. (see formula I)
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07C 235/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 317/44 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
C07C 321/14 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
C07C 333/04 - Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent such as ethanol, and injecting this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water to produce nanoparticles having a mean size of 50 to 150 nm and a final charge ratio of drug:lipid is 1 :2.5.
The present invention pertains to a material delivery carrier for extracellular matrix-producing cells in the intestines, the carrier comprising a retinoid as a targeting agent, as well as to an intestinal fibrosis treatment agent using the carrier.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 45/08 - Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Sterile preparation of a lipid-drug nanoparticle includes transferring an aqueous drug solution from a first holding unit to a mixing unit and adding a solution of lipids in a water-miscible organic solvent from a second holding unit to the aqueous drug solution, using injection means so as to form a gradient of the organic solvent concentration in the solution in the mixing unit. The resulting lipid-drug mixture is diluted with an aqueous buffer to form a liposome suspension, which is then concentrated using a transflow filter to remove the organic solvent. The concentrated liposome suspension is collected in a single use bed for subsequent aseptic dispensing. Apparatus used to carry out the process contains components which are sterilized and disposable so as to be adapted for single batch usage.
The present invention provides an adhesive patch comprising a support, an adhesive layer on at least one surface of the support, and a release liner on a surface of the adhesive layer opposite from the support, wherein (a) the lateral end of the adhesive layer is exposed, (b) in at least one lateral end, the lateral end of the adhesive layer is located toward the central part side of the adhesive patch from the lateral end of the support, and (c) when placed horizontally with the release liner facing down, a distance A between the upper end of the support and the lower end of the release liner at said lateral end of the adhesive patch is greater than a thickness B of the central part of the adhesive patch.
The present invention provides a patch preparation that has an extremely low moisture permeability, has a sufficient ODT effect, is excellent in drug releasability and in anchoring property of its drug-containing pressure-sensitive adhesive layer, and has a preferred patch feeling. The patch preparation of the present invention includes a support; and a pressure-sensitive adhesive layer containing an adherent polymer and a drug on one surface of the support, wherein: the support has a polyester base layer, an inorganic oxide layer, and a polyester nonwoven fabric layer in the stated order; the polyester base layer has a thickness of 1.0 µm to 16 µm; and the pressure-sensitive adhesive layer is laminated on the polyester nonwoven fabric layer.
This invention relates to: a novel use of GST-n and GST-n suppressing agents; an apoptosis-inducing agent containing as active components a drug that suppresses GST-n and a drug that suppresses autophagy; a medical composition containing said agent; and a method using said medical composition for treating diseases associated with abnormal apoptosis.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPTNHl_45a (SEQ ID NOS: 98 and 165), and SERPTNH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
Compounds of the structure (retinoid)m-linker-(retinoid)n wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG), PEG- like molecule, Glu, G1y3 and/or GluNH are useful for facilitating drug delivery to a target cell. The retinoid may have a specific receptor or activation/binding site on the target cell.
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
53.
COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY
Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent; wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4; wherein a = 1 -4; wherein b=l -4; wherein c=l-4; and wherein Z is a counterion; and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07C 323/60 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
C07C 333/04 - Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
The problem of the present invention is to provide a patch preparation containing a drug (excluding 2-(4-ethyl-1- piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10- hexahydrocycloocta[b]pyridine and a physiologically acceptable acid addition salt thereof), which is superior in both the skin permeability of a drug, and adhesiveness in the presence of water. A patch preparation containing a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a drug excluding 2-(4-ethyl-1-piperazinyl)-4-(4- fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine and a physiologically acceptable acid addition salt thereof, an acrylic polymer, lactic acid and magnesium aluminometasilicate.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The problem of the present invention is to provide a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bleed even when an organic fluid component having high polarity is contained. A patch containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 500,000- 1,600,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.
The problem of the present invention is to provide a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bleed even when an organic fluid component having high polarity is contained. A patch containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 1,700,000 - 6,500,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.
An optical measurement device and method of use provides non-invasive physiological measurements from a predetermined location on a body part of a user. The optical measurement device provides an illumination and detection assembly configured to generate and detect light of a predetermined wavelength range in the form of a photoplethysmography (PPG) signal, as well as a pressure detection assembly configured to detect an amount of pressure applied to the measurement device by the user being measured. A feedback unit, such as a portable display device, can be coupled to the measurement device to provide the user with real-time feedback of the detected PPG signal and level of applied pressure so that the user may adjust the amount of applied pressure to improve the quality of the detected PPG signal.
A61B 5/0295 - Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
58.
COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE
The invention pertains to a pharmaceutical composition and method for regenerating normal tissue from fibrotic tissue that comprise a collagen-reducing substance. The invention makes possible the therapeutic regeneration of normal tissue from fibrotic tissue.
The present invention relates to a substance delivery carrier for extracellular matrix-producing cells in the kidney, the carrier including a retinoid as a targeting agent, an agent for treating renal fibrosis utilizing the carrier, a process for producing them, a production kit, a method for treating renal fibrosis using the agent for treating renal fibrosis, etc.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
60.
LAMINATE STRUCTURE WITH EMBEDDED CAVITIES AND RELATED METHOD OF MANUFACTURE
An integrated laminate structure (202, 302, 402, 502, 602, 702a, 702b, 801, 902, 1002, 1216) adapted for application in the context of solar technology, wafer technology, cooling channels, greenhouse illumination, window illumination, street lighting, traffic lighting, traffic reflectors or security films, comprising a first carrier element (206, 304, 406, 505, 506, 606, 704, 804, 1006, 1204) such as a piece of plastic or glass, optionally comprising optically substantially transparent material enabling light transmission therethrough, a second carrier element (204, 306, 404, 504, 505, 604, 702, 802, 1004, 1206) provided with at least one surface relief pattern (308, 802a, 1206b) comprising a number of surface relief forms (208, 308a, 308b, 408, 412, 508, 510, 608, 610, 708) and having at least one predetermined optical function (708a, 710, 712) relative to incident light, said second carrier element optionally comprising optically substantially transparent material enabling light transmission therethrough, the first and second carrier elements being laminated together such that the at least one surface relief pattern has been embedded within the established laminate structure and a number of related cavities (210, 308b, 408, 410, 412, 508, 510, 608, 610, 709) have been formed at the interface of said first and second carrier elements. An applicable method of manufacture is presented.
B32B 3/26 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a layer with cavities or internal voids
B32B 37/00 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
Provided is a patch preparation containing: a support; and an adhesive layer containing a drug on the surface of the support, wherein a crystal of the drug is formed in the adhesive layer immediately after application of a physical stimulation to the adhesive layer, while a crystal of the drug is formed during preservation after the physical stimulation. According to the present invention, a patch preparation which does not require increase in the area and thickness of an adhesive layer, achieves sufficiently high skin permeation amount of a drug, shows good adhesiveness to the skin and permits a long-term adhesion, and a production method thereof can be provided.
Disclosed is an adhesive skin patch containing medication other than bisoprolol. Specifically disclosed is an adhesive skin patch which is suppressed in the occurrence of oozing or squeezing-out of the components of the adhesive layer of the adhesive skin patch from the exposed section of the adhesive layer and in the reduction of a medication content due to the oozing of the medication from the adhesive layer, which occur while the adhesive skin patch is stored. Each of a support, a peeling liner, and the adhesive layer and the whole of the adhesive skin patch have a rectangular planar shape, projecting sections being respectively provided on the support-side surface at the corners of the adhesive skin patch. Moreover, it is possible to provide the center section and the circumferential section in the adhesive skin patch and to provide projecting sections at the corners of the rectangular shape of the center section. Furthermore, it is possible to provide, between two or more adjacent projecting sections, raised connecting sections where the adhesive skin patch is thinner than in the projecting sections. If providing a back split section in the peeling liner, the back split section is made to avoid passing through the projecting sections.
Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The patch according to an embodiment of the present invention includes: a support; and a pressure-sensitive adhesive layer on at least one surface of the support, wherein: the pressure-sensitive adhesive layer contains an acrylic copolymer obtained by copolymerizing monomer components containing (a) at least one kind of a monomer of a (meth)acrylic acid alkyl ester and (b) at least one kind of a monomer of an N- hydroxyalkyl(meth)acrylamide; a content of the (meth)acrylic acid alkyl ester monomer (a) with respect to a total amount of the monomer components is 50 wt% to 90 wt% and a content of the N--hydroxyalkyl(meth)acrylamide monomer (b) with respect to the total amount is 1 wt% to 20 wt%; and the monomer components are substantially free of a monomer having a carboxyl group.
There is provided a medical pressure-sensitive adhesive composition including an acrylic copolymer obtained by copolymerizing monomer components containing (a) at least one kind of a monomer of a (meth)acrylic acid alkyl ester and (b) at least one kind of a monomer of an N-hydroxyalkyl(meth)acrylamide, wherein: a content of the (meth)acrylic acid alkyl ester monomer (a) with respect to a total amount of the monomer components is 50 weight% to 99.9 weight% and a content of the N-hydroxyalkyl(meth)acrylamide monomer (b) with respect to the total amount is 0.1 weight% to 20 weight%; and the monomer components are substantially free of a monomer having a carboxyl group. The medical pressure-sensitive adhesive composition of the present invention is particularly suitable for applications such as medical patches and patch preparations.
C09J 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
C09J 133/24 - Homopolymers or copolymers of amides or imides
The invention provides an extrusion material supply device suitable for use in melt extrusion molding, and a method for manufacturing an optical transmission body, in which a deterioration of an optical signal transmission loss is extremely small, and productivity intrinsic to an extrusion molding method is provided in combination. An extrusion material supply device 1 includes: a vertical hopper 2, which has a cooling unit 3 and a heat melting unit 4 continuous with a lower portion thereof, and houses a material rod R; cooling means 5 for cooling the cooling unit 3; an electric heater 6 that heats the heat melting unit 4; and gas pressurizing means 7 for sequentially supplying molten plastics M to a metal die by a gas pressure. The heat melting unit 4 is formed into a cylinder shape in which an inner diameter is larger than an inner diameter of the cooling unit 3 arranged above, and enables the molten plastics M to spread in the heat melting unit 4. A portion between an outer circumference of the material rod R and an outer circumference of the molten plastics M is defined as an annular gas pressurizing surface 7a.
The present invention provides to a patch and a patch preparation having low stretchability, which can be continuously adhered to the skin for a long time without undesirable detachment and marked falling off from the skin due to various factors during adhesion, and specifically provides a low stretchable patch and a patch preparation containing a support and an adhesive layer formed on one surface of the support, wherein a ratio P of the total length W (mm) of curved sections of a planar outer shape of the patch to the total length S (mm) of straight-line sections of the planar outer shape of the patch (W/S) is not more than 1.22, and, when the curved sections are approximated by a circular arc, the radius R (mm) of the circular arc is not less than 0.5 mm.
A patch package structure which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, a peripheral area of the first sheet material having been sealed to a peripheral area of the second sheet material to constitute the package, and a patch disposed in the package; in which the patch includes a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner which protects the pressure- sensitive adhesive surface of the pressure-sensitive adhesive layer, the release liner having a weakening line for assisting a removal of the release liner; and in which the second sheet material has specific first protrudent part, second protrudent part, third protrudent part and elevated part in a central area thereof except the peripheral area thereof.
B65D 75/34 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents and having several recesses to accommodate a series of articles or quantities of material
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
Provision of a blister package that cannot be opened easily by infants, but can be opened easily, certainly and safely by a user when in use. A blister package 100 containing a blister 1 and a cover sheet 2, wherein the blister has a groove 3 formed in an outer edge section 1A thereof where the cover sheet is adhered and the groove 3 is free of adhesion of the sheet. The cover sheet is adhered to the outermost circumference la of the outer edge section 1A, the groove 3 is formed on the inward side of the outermost circumference la, and the cover sheet is not adhered to the area on the inward side of the groove 3.
B65D 75/36 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages
Disclosed is a substance delivery carrier for an extracellular-matrix- producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular-matrix-producing cell in the bone marrow.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
An adhesive patch containing an adhesive patch main part containing a support and an adhesive layer laminated on the support, wherein the adhesive patch main part comprises a peripheral part, a central part, and an intermediate part between the peripheral part and the central part, the intermediate part of the adhesive patch main part has a thickness greater than that of the central part of the adhesive patch main part, and the central part of the adhesive patch main part has a thickness greater than that of the peripheral part of the adhesive patch main part, and a production method thereof.
The invention provides a process for producing an adhesive patch, which includes a step of preparing a pressure-sensitive adhesive sheet including a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner disposed on the pressure-sensitive adhesive layer; and a step of punching an adhesive patch including a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner disposed on the pressure- sensitive adhesive layer out of the pressure-sensitive adhesive sheet with a protrudent push cutter blade, in which, at at least an edge part of the protrudent push cutter blade, a cross-sectional shape of the protrudent push cutter blade, which is in a direction perpendicular to the direction in which the protrudent push cutter blade extends, has an angle .alpha. and an angle b, in which the angle .alpha. is larger than the angle b. The angle .alpha. and angle b in the sectional shape have the meanings described in the specification.
Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 11/00 - Drugs for disorders of the respiratory system
The invention relates to a patch including a backing, a pressure-sensitive adhesive layer, and a release liner, the patch at an edge part thereof having such a sectional shape that, when a perpendicular segment is drawn from an edge of the backing at the edge part of the patch to the release liner, at least a part of an edge of the pressure-sensitive adhesive layer at the edge part of the patch is located on the center side of the patch with respect to the segment, and the edge of the pressure- sensitive adhesive layer being exposed. According to the invention, a patch and an adhesive preparation in each of which the pressure-sensitive adhesive is less apt to protrude or flow out from the edges thereof can be provided.
The present invention provides a patch package structure, which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, the first and second sheet materials being sealed together in peripheral parts thereof, and a patch disposed in the package, in which the patch contains a backing, a pressure-sensitive adhesive layer laminated on at least one side of the backing, and a release liner which protects a pressure-sensitive adhesive surface of the pressure-sensitive adhesive layer; the second sheet material has been molded so as to have a protrudent part in at least a substantially central area thereof, the protrudent part having a planar outer shape larger than a planar outer shape of the release liner and having at least one recessed part; d is not smaller than T, in which d is the minimum gap distance between the inner surface of the first sheet material and the inner surface of the second sheet material at the recessed part and T is a thickness of the patch; and, at the boundary between the sealed part where the first and second sheet materials are sealed together and an unsealed part, the outer surface of the second sheet material rises at an obtuse angle.
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
B65D 85/00 - Containers, packaging elements or packages, specially adapted for particular articles or materials
76.
MANUFACTURING APPARATUS OF TRANSDERMAL ABSORPTION PREPARATION
A manufacturing apparatus of a transdermal absorption preparation, comprising an adhesive sheet supplying part A to feed out a band-like first adhesive sheet 3 into a runway, wherein the adhesive sheet has at least an adhesive layer comprising an adhesive and a liquid component compatible with the adhesive, a drug liquid application part B to apply a given amount of a drug liquid to an adhesive face 2b, and a traveling section C for impregnation which is set in the runway after the drug liquid application part B, during which the adhesive sheet is run for a period necessary for the applied drug liquid to soak into the adhesive layer without contact of the drug liquid coated face of the adhesive layer with other members.
The invention provides an adhesive preparation including a backing, and a pressure-sensitive adhesive layer which contains a drug and is disposed on at least one side of the backing; in which the backing includes a polyester film having a thickness of 0.5 to 6.0 µm, and a polyester nonwoven fabric directly bound to the film. The pressure-sensitive adhesive layer preferably is directly or indirectly laminated on the nonwoven-fabric side of the backing. The adhesive preparation of the invention is flexible enough to comply to the skin and has reduced skin irritation and high stability.
In the adhesive pharmaceutical preparation of the invention, a pressure- sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer contains a branched monoalcohol having from 12 to 28 carbon atoms, a drug which is liquid at room temperature or around room temperature (in which, free base of bisoprolol is excluded) and a polyisobutylene pressure-sensitive adhesive. Accordingly, compatibility of the polyisobutylene pressure-sensitive adhesive with the drug can be specifically increased. As a result, not only it becomes possible to increase blending amount of the drug but also bleed of the drug from the pressure- sensitive adhesive layer can be suppressed and, what is more, the pressure-sensitive adhesion characteristics sufficient from the practical point of view can be obtained.
A percutaneous absorption-type pharmaceutical preparation containing a sublimation drug is provided, where from a plaster layer, a drug is released as volatile substance with a lapse of time, but the released drug has no adverse effect on the handling of the preparation, and the quality of the preparation is maintained in storage over a long period of time. A percutaneous absorption-type pharmaceutical preparation, which comprises: a support comprising a plastic film and a nonwoven fabric; and a plaster layer containing a sublimation drug, wherein the plastic film and the nonwoven fabric are laminated with an adhesive having a glass transition temperature of 10°C or higher, and the plaster layer is laminated on opposite side of the plastic film surface that the nonwoven fabric is laminated with.
The present invention provides an adhesive capable of affording an adhesive layer showing reduced stickiness, reduced cohesive failure and the like. An adhesive containing a copolymer obtained by copolymerizing monomers containing a (meth)acrylic acid alkyl ester as a main component, and a vinyl monomer having a hydroxyl group and/or a carboxyl group and which has an average molecular radius of not less than 70 nm as measured by a multi angle laser light scattering method.
An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
82.
DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS
An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
The present invention provides an adhesive material to be adhered to the skin etc., which maintains, for a certain time period after adhesion thereof to the skin surface, suitable adhesiveness that does not allow easy peeling or cause irritation to the skin, and which permits, when it is to be peeled off from the skin surface after the lapse of a desired certain time period, easy peeling without causing pain or physical irritation, and an adhesive preparation containing the adhesive material and a percutaneously absorbable drug in the adhesive layer. Specifically, the present invention provides an adhesive material containing a support and an adhesive layer laminated on one surface of the support, wherein the adhesive layer has an apparent viscosity at 30°C of 0.2×10 4 to 10×10 4Pa.cndot.s and comprises two kinds of synthetic rubbers having different flowability.
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
The present invention provides an adhesive preparation package containing an adhesive preparation and a packaging film(s) enclosing said preparation, the packaging films being heat-sealed around the adhesive preparation, wherein the heat-sealed portion of the packaging film comprises an embossed heat-sealed portion and a flat heat-sealed portion, and the embossed heat-sealed portion and the flat heat-sealed portion each form a pattern surrounding the periphery of the adhesive preparation. The adhesive preparation package of the present invention is free of occurrence of pinholes in a heat-sealed portion and can maintain superior air-tightness and sterility.
B65D 75/30 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
B65B 11/50 - Enclosing articles, or quantities of material, by disposing contents between two sheets, e.g. pocketed sheets, and securing their opposed free margins
B65D 75/20 - Articles or materials wholly enclosed in single sheets or wrapper blanks in sheets or blanks doubled around contents and having their opposed free margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
The present invention provides, as a resin bead which can be developed for use completely different from the use of conventional polystyrene resin beads, a porous resin bead made from a styrene-hydroxystyrene-divinylbenzene copolymer, which contain a hydroxyl group in an amount of 10 - 1000 µmol/g, and further, a production method of a porous resin bead made from a styrene-hydroxystyrene-divinylbenzene copolymer; which contains suspension copolymerization of a styrene monomer, an acyloxystyrene monomer and a divinylbenzene monomer using an organic solvent (containing at least hydrocarbon and alcohol) and water, followed by hydrolysis reaction.
C08F 212/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms
patents
